Oruka Therapeutics, Inc. financial data

Symbol
ORKA on Nasdaq
Industry
Pharmaceutical Preparations
Location
855 Oak Grove Ave., Suite 100, Menlo Park, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
ARCA biopharma, Inc. (to 8/30/2024), NUVELO INC (to 1/27/2009), HYSEQ INC (to 1/28/2003)
Latest financial report
10-K - Q4 2024 - Mar 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.54K % -28.3%
Debt-to-equity 5.16 % +47%
Return On Equity -48.6 % -252%
Return On Assets -38 % -185%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 37.4M shares +158%
Common Stock, Shares, Outstanding 37.4M shares +158%
Entity Public Float 39.7M USD +89.8%
Common Stock, Value, Issued 37K USD +164%
Weighted Average Number of Shares Outstanding, Basic 16.8M shares +16.5%
Weighted Average Number of Shares Outstanding, Diluted 16.8M shares +16.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Research and Development Expense 75.1M USD +7310%
General and Administrative Expense 13.1M USD +108%
Operating Income (Loss) -88.1M USD -1108%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -83.7M USD -1468%
Earnings Per Share, Basic -3.87 USD/shares -946%
Earnings Per Share, Diluted -3.87 USD/shares -946%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 61.6M USD +64.5%
Marketable Securities, Current 314M USD
Other Assets, Current 537K USD -10.4%
Assets, Current 377M USD +903%
Property, Plant and Equipment, Net 162K USD +1520%
Operating Lease, Right-of-Use Asset 876K USD +255%
Other Assets, Noncurrent 43K USD +258%
Assets 396M USD +946%
Accounts Payable, Current 571K USD +137%
Employee-related Liabilities, Current 109K USD -42.6%
Liabilities, Current 13M USD +1948%
Operating Lease, Liability, Noncurrent 755K USD +270%
Liabilities 13.8M USD +1541%
Accumulated Other Comprehensive Income (Loss), Net of Tax -41K USD
Retained Earnings (Accumulated Deficit) -83.7M USD +55.6%
Stockholders' Equity Attributable to Parent 382M USD +932%
Liabilities and Equity 396M USD +946%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.53M USD +4.2%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 545M shares +445%
Common Stock, Shares, Issued 37.4M shares +158%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.53M USD +4.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 61.6M USD +64.5%
Deferred Tax Assets, Valuation Allowance 21.3M USD -61.6%
Deferred Tax Assets, Gross 21.5M USD -61.3%
Operating Lease, Liability 968K USD +246%
Lessee, Operating Lease, Liability, to be Paid 1.24M USD +296%
Property, Plant and Equipment, Gross 222K USD -3.06%
Operating Lease, Liability, Current 213K USD +180%
Lessee, Operating Lease, Liability, to be Paid, Year Two 494K USD +415%
Lessee, Operating Lease, Liability, to be Paid, Year One 369K USD +297%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 275K USD +709%
Lessee, Operating Lease, Liability, to be Paid, Year Three 380K USD +280%
Deferred Tax Assets, Operating Loss Carryforwards 2.26M USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 1.05M USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 25K USD -75%
Operating Lease, Payments 23K USD -30.3%
Additional Paid in Capital 463M USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 63K USD -29.2%
Share-based Payment Arrangement, Expense 14.9M USD +2075%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%